Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

被引：0

作者：

Atsuo Takashima

Kohei Shitara

Kazumasa Fujitani

Keisuke Koeda

Hiroki Hara

Norisuke Nakayama

Shuichi Hironaka

Kazuhiro Nishikawa

Yutaka Kimura

Kenji Amagai

Hirofumi Fujii

Kei Muro

Taito Esaki

Yasuhiro Choda

Toshimi Takano

Keisho Chin

Atsushi Sato

Masahiro Goto

Norimasa Fukushima

Takuo Hara

Nozomu Machida

Manabu Ohta

Narikazu Boku

Masashi Shimura

Satoshi Morita

Wasaburo Koizumi

机构：

[1] National Cancer Center Hospital,Gastrointestinal Medical Oncology Division

[2] National Cancer Center Hospital East,Department of Gastrointestinal Oncology

[3] Osaka General Medical Center,Department of Surgery

[4] Iwate Medical University School of Medicine,Department of Surgery

[5] Saitama Cancer Center,Department of Gastroenterology

[6] Kanagawa Cancer Center,Department of Gastroenterology

[7] Chiba Cancer Center,Clinical Trial Promotion Department

[8] National Hospital Organization Osaka National Hospital,Department of Surgery

[9] Sakai City Medical Center,Department of Surgery

[10] Ibaraki Prefectural Central Hospital,Department of Gastroenterology

[11] Jichi Medical University Hospital,Department of Clinical Oncology

[12] Aichi Cancer Center Hospital,Department of Clinical Oncology

[13] National Kyushu Cancer Center,Department of Gastrointestinal and Medical Oncology

[14] Hiroshima City Hiroshima Citizens Hospital,Department of Surgery

[15] Toranomon Hospital,Department of Medical Oncology

[16] Cancer Institute Hospital of the Japanese Foundation for Cancer Research,Department of Gastroenterology

[17] Hirosaki University Graduate School of Medicine,Department of Medical Oncology

[18] Osaka Medical College Hospital,Cancer Chemotherapy Center

[19] Yamagata Prefectural Central Hospital,Department of Surgery

[20] Kouseiren Takaoka Hospital,Department of Surgery

[21] Shizuoka Cancer Center,Division of Gastrointestinal Oncology

[22] Hamamatsu University School of Medicine,Oncology Center

[23] Taiho Pharmaceutical. Co.,Data Science Department

[24] Ltd.,Department of Biomedical Statistics and Bioinformatics

[25] Kyoto University Graduate School of Medicine,Department of Gastroenterology

[26] Kitasato University School of Medicine,undefined

来源：

Gastric Cancer | 2019年 / 22卷

关键词：

Peritoneal metastasis; Nab-paclitaxel; Solvent-based paclitaxel; Second-line chemotherapy; Predictive factor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：155 / 163

页数：8

共 50 条

[1] Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial
Takashima, Atsuo
Shitara, Kohei
Fujitani, Kazumasa
Koeda, Keisuke
Hara, Hiroki
Nakayama, Norisuke
Hironaka, Shuichi
Nishikawa, Kazuhiro
Kimura, Yutaka
Amagai, Kenji
Fujii, Hirofumi
Muro, Kei
Esaki, Taito
Choda, Yasuhiro
Takano, Toshimi
Chin, Keisho
Sato, Atsushi
Goto, Masahiro
Fukushima, Norimasa
Hara, Takuo
Machida, Nozomu
Ohta, Manabu
Boku, Narikazu
Shimura, Masashi
Morita, Satoshi
Koizumi, Wasaburo
GASTRIC CANCER, 2019, 22 (01) : 155 - 163
[2] Drug selection by Narrative approach in patients with advanced gastric cancer -Paclitaxel or nab-Paclitaxel?-
Kawase, Tomono
Imamura, Hiroshi
Hirota, Masashi
Nagase, Hirotsugu
Noura, Shingo
Tanida, Tsukasa
Noguchi, Kouzou
Ooshima, Kazuki
Akagi, Kenzou
Iwazawa, Takushi
Douno, Keizou
ANNALS OF ONCOLOGY, 2019, 30 : 99 - 99
[3] A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)
Koizumi, Wasaburo
Morita, Satoshi
Sakata, Yuh
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (03) : 303 - 306
[4] Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Horita, Y.
Mihara, Y.
Hamaguchi, T.
ANNALS OF ONCOLOGY, 2019, 30
[5] Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy
Kanazawa, Yoshikazu
Fujita, Itsuo
Kakinuma, Diasuke
Arai, Hiroki
Matsuno, Kunihiko
Shimoda, Tomohiro
Ko, Kazuhide
Kato, Shunji
Uchida, Eiji
ANTICANCER RESEARCH, 2017, 37 (05) : 2715 - 2720
[6] A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis
Naminatsu Takahara
Yousuke Nakai
Hironori Ishigami
Kei Saito
Tatsuya Sato
Ryunosuke Hakuta
Kazunaga Ishigaki
Tomotaka Saito
Tsuyoshi Hamada
Suguru Mizuno
Hirofumi Kogure
Hiroharu Yamashita
Hiroyuki Isayama
Yasuyuki Seto
Kazuhiko Koike
Investigational New Drugs, 2021, 39 : 175 - 181
[7] A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis
Takahara, Naminatsu
Nakai, Yousuke
Ishigami, Hironori
Saito, Kei
Sato, Tatsuya
Hakuta, Ryunosuke
Ishigaki, Kazunaga
Saito, Tomotaka
Hamada, Tsuyoshi
Mizuno, Suguru
Kogure, Hirofumi
Yamashita, Hiroharu
Isayama, Hiroyuki
Seto, Yasuyuki
Koike, Kazuhiko
INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 175 - 181
[8] Correlation between SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine: An exploratory analysis of a phase II trial, CCOG1303
Kobayashi, D.
Enomoto, A.
Mochizuki, Y.
Matsui, T.
Nakayama, H.
Kawase, Y.
Ishigure, K.
Shikano, T.
Torii, K.
Kodera, Y.
ANNALS OF ONCOLOGY, 2017, 28
[9] nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial
Gridelli, Cesare
Chen, Tianlei
Ko, Amy
O'Brien, Mary E.
Ong, Teng Jin
Socinski, Mark A.
Postmus, Pieter E.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1445 - 1451
[10] A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
Bando, Hideaki
Shimodaira, Hideki
Fujitani, Kazumasa
Takashima, Atsuo
Yamaguchi, Kensei
Nakayama, Norisuke
Takahashi, Takehiro
Oki, Eiji
Azuma, Mizutomo
Nishina, Tomohiro
Hironaka, Shuichi
Komatsu, Yoshito
Shitara, Kohei
EUROPEAN JOURNAL OF CANCER, 2018, 91 : 86 - 91

← 1 2 3 4 5 →